| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f2feed77ad2920b465a9409f31480591
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_aac75cea58f1ede8e6c2ccac499a1576
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_53e211d36ea18a28b99b1bc957d36990
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0fef8b7af1d2d5e5bbad7ad023c8a2fb
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8bdfd6e8d4134430cb7a0e01863a7322
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_39efb90af4e222fee57d8a8999c0f4f4 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-24043
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2740-16134
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2740-16034
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-545
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-53
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-57 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-21 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-21 |
| filingDate |
2001-01-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_08cf132d78264b952bf9d5eabe7c72b7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9a9098f369816eab5076072d7400d919
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_18d6f7d8c7764ef1228463d5c25e8e81
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f106d61e9d6aeeed7bc6e19aab3e930b |
| publicationDate |
2001-08-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-0154701-A1 |
| titleOfInvention |
Vaccination of hiv infected persons following highly active antiretroviral therapy |
| abstract |
The present invention provides a method of permitting cessation of antiviral therapy on HIV-infected subjects without virus rebound or with at least a delayed virus rebound or a decreased post rebound set-point. The method comprises the re-induction of HIV-specific immune responses using a vaccination strategy to induce both humoral and cell-mediated immunity. The present invention achieves an immunological control of persistent infectious virus after discontinuation of antiviral therapy. The vaccine strategy according to the invention is both safe and immunogenic in the subject HIV-infected patient population. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2987500-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7888003-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2011035082-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2005027835-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2005027835-A3
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7943375-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9121855-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AU-2010295497-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2007018550-A3
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2295974-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8133494-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2007515386-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8722324-B2 |
| priorityDate |
2000-01-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |